388 related articles for article (PubMed ID: 26317203)
21. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
22. A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29.
Novotny A; Edsparr K; Nylund G; Khorram-Manesh A; Albertsson P; Nordgren S; Delbro DS
Eur J Pharmacol; 2010 Nov; 646(1-3):22-30. PubMed ID: 20727878
[TBL] [Abstract][Full Text] [Related]
23. Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential.
Techavichit P; Gao Y; Kurenbekova L; Shuck R; Donehower LA; Yustein JT
BMC Cancer; 2016 Nov; 16(1):869. PubMed ID: 27821163
[TBL] [Abstract][Full Text] [Related]
24. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
25. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
26. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
27. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
28. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.
Ahmad A; Kong D; Wang Z; Sarkar SH; Banerjee S; Sarkar FH
J Cell Biochem; 2009 Nov; 108(4):916-25. PubMed ID: 19693769
[TBL] [Abstract][Full Text] [Related]
30. Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.
Rao Gogineni V; Kumar Nalla A; Gupta R; Gorantla B; Gujrati M; Dinh DH; Rao JS
Int J Oncol; 2010 Apr; 36(4):809-16. PubMed ID: 20198323
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma.
Su Y; Wagner ER; Luo Q; Huang J; Chen L; He BC; Zuo GW; Shi Q; Zhang BQ; Zhu G; Bi Y; Luo J; Luo X; Kim SH; Shen J; Rastegar F; Huang E; Gao Y; Gao JL; Yang K; Wietholt C; Li M; Qin J; Haydon RC; He TC; Luu HH
Oncogene; 2011 Sep; 30(37):3907-17. PubMed ID: 21460855
[TBL] [Abstract][Full Text] [Related]
32. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
33. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
34. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Paland N; Gamliel-Lazarovich A; Coleman R; Fuhrman B
Atherosclerosis; 2014 Nov; 237(1):200-7. PubMed ID: 25244504
[TBL] [Abstract][Full Text] [Related]
35. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Stahl A; Mueller BM
Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
[TBL] [Abstract][Full Text] [Related]
36. Mediator of RNA polymerase II transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis.
Yu W; Zhang Z; Min D; Yang Q; Du X; Tang L; Lin F; Sun Y; Zhao H; Zheng S; He A; Li H; Yao Y; Shen Z
Eur J Cancer; 2014 Apr; 50(6):1125-36. PubMed ID: 24565852
[TBL] [Abstract][Full Text] [Related]
37. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
38. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
39. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
40. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
Kiyan J; Smith G; Haller H; Dumler I
Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
